The World Dispatch

Walking the talk, Kyverna phase II stiffens miv-cel CAR T case

April 22, 2026

Walking the talk, Kyverna phase II stiffens miv-cel CAR T case

Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a positive primary analysis from its registrational trial, KYSA-8, of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff-person syndrome. Kyverna plans to submit a BLA to the U.S. FDA in the first half of this year.

Source: bioworld

Publication

The World Dispatch

Source: World News API

Keywords: autoimmune disease, american academy of neurology, neurology/psychiatric, kyverna therapeutics inc., myasthenia gravis, kyv-101, u.s., car t, appointments and advancements, conferences, clinical, mivocabtagene autoleucel, stiff-person syndrome, bioworld, briefs, miv-cel, immune, ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS